CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Wekking, Demi; Lambertini, Matteo; Dessì, Mariele; Denaro, Nerina; Bardanzellu, Fabio; Garrone, Ornella; Scartozzi, Mario; Solinas, Cinzia

doi:10.1053/j.seminoncol.2024.01.002

Cited by 4 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exposure to chemicals: Chemicals like endocrine disruptors may disrupt hormonal balance, potentially contributing to breast cancer ( 105 ). evaluates CDK4/6 inhibitors’ toxicity in metastatic breast cancer, stressing personalized treatment strategies due to varying drug profiles.…”

Section: Resultsmentioning

confidence: 99%

A contemporary review of breast cancer risk factors and the role of artificial intelligence

Nicolis,

De Los Angeles,

Taramasco

2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundBreast cancer continues to be a significant global health issue, necessitating advancements in prevention and early detection strategies. This review aims to assess and synthesize research conducted from 2020 to the present, focusing on breast cancer risk factors, including genetic, lifestyle, and environmental aspects, as well as the innovative role of artificial intelligence (AI) in prediction and diagnostics.MethodsA comprehensive literature search, covering studies from 2020 to the present, was conducted to evaluate the diversity of breast cancer risk factors and the latest advances in Artificial Intelligence (AI) in this field. The review prioritized high-quality peer-reviewed research articles and meta-analyses.ResultsOur analysis reveals a complex interplay of genetic, lifestyle, and environmental risk factors for breast cancer, with significant variability across different populations. Furthermore, AI has emerged as a promising tool in enhancing the accuracy of breast cancer risk prediction and the personalization of prevention strategies.ConclusionThe review highlights the necessity for personalized breast cancer prevention and detection approaches that account for individual risk factor profiles. It underscores the potential of AI to revolutionize these strategies, offering clear recommendations for future research directions and clinical practice improvements.

show abstract

Section: Resultsmentioning

confidence: 99%

A contemporary review of breast cancer risk factors and the role of artificial intelligence

Nicolis,

De Los Angeles,

Taramasco

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, a recent study of HR+, HER2− metastatic breast cancer patients receiving palbociclib-based therapy reported a similar prevalence of adverse effects to treatment and minimal differences in prevalence of specific adverse effects such as neutropenia, diarrhea, and fatigue between patients <70 and patients ≥70 over the course of the first six months of treatment [48]. Another study assessed the difference in prevalence of specific adverse effects associated with palbociclib, ribociclib, and abemaciclib and found neutropenia to be more prevalent in patients receiving palbociclib-based therapy and diarrhea to be more prevalent in patients receiving abemaciclib-based therapy [49]. Thus, nuances in the duration of treatment and the specific CDK4/6 inhibitor used may be responsible for discrepant findings regarding adverse effects and must be considered when assessing treatment-related toxicities.…”

Section: Discussionmentioning

confidence: 99%

Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy

O’Connor,

Schultz,

Wang

et al. 2024

Cancers

View full text Add to dashboard Cite

The largest portion of breast cancer patients diagnosed after 70 years of age present with hormone receptor-positive (HR+) breast cancer subtypes. Cyclin-dependent kinase (CDK) 4/6 inhibitor treatment, in conjunction with endocrine therapy, has become standard-of-care for metastatic HR+ breast cancer. In total, 320 patients with metastatic breast cancer receiving CDK4/6 inhibitor combined with fulvestrant or an aromatase inhibitor were enrolled in an ongoing observational study or were included in an IRB-approved retrospective study. All patients receiving CDK4/6 inhibitor-based therapy that were ≥70 years of age (n = 111) displayed prolonged progression-free survival (27.6 months) as compared to patients <70 years of age (n = 209, 21.1 months, HR = 1.38, p < 0.05). Specifically, patients receiving a CDK4/6 inhibitor with an aromatase inhibitor who were ≥70 years of age (n = 79) displayed exceptionally prolonged progression-free survival (46.0 months) as compared to patients receiving the same treatment who were <70 years of age (n = 161, 21.8 months, HR = 1.71, p < 0.01). However, patients ≥70 years of age also experienced more frequent adverse responses to CDK4/6 inhibitor-based treatment leading to dose reduction, hold, or discontinuation than the younger cohort (69% and 53%, respectively). Treatment strategies that may decrease toxicity without affecting efficacy (such as dose titration) are worth further exploration.

show abstract

Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis

Yang,

Zhang,

et al. 2024

Eur J Clin Pharmacol

View full text Add to dashboard Cite

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Cited by 4 publications

References 76 publications

A contemporary review of breast cancer risk factors and the role of artificial intelligence

A contemporary review of breast cancer risk factors and the role of artificial intelligence

Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy

Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis

Contact Info

Product

Resources

About